Halozyme Therapeutics (HALO) Inventory Average (2011 - 2026)

Halozyme Therapeutics (HALO) has 16 years of Inventory Average data on file, last reported at $166.0 million in Q1 2026.

• On a quarterly basis, Inventory Average rose 8.22% year-over-year to $166.0 million in Q1 2026; TTM through Mar 2026 was $166.0 million, a 8.22% increase from a year earlier, with the FY2025 full-year figure at $159.2 million, up 18.14% from the prior year.
• Inventory Average for Q1 2026 stood at $166.0 million, down from $181.1 million in the prior quarter.
• Over the last five years, Inventory Average for HALO reached as high as $183.7 million in Q3 2025 and fell as low as $50.8 million in Q1 2022.
• Historically, Inventory Average has averaged $132.9 million across 5 years, with a median of $136.6 million in 2024.
• Across the five-year window, Inventory Average decreased 14.63% in 2022 and soared 104.24% in 2023, its largest moves.
• Year by year, Inventory Average stood at $101.7 million in 2022, then climbed by 26.12% to $128.3 million in 2023, then advanced by 6.53% to $136.6 million in 2024, then soared by 32.57% to $181.1 million in 2025, then dropped by 8.37% to $166.0 million in 2026.
• Per Business Quant data, the three most recent Inventory Average figures were $166.0 million in Q1 2026, $181.1 million in Q4 2025, and $183.7 million in Q3 2025.